Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment (2016 - 2018)

Ironwood Pharmaceuticals' Asset Writedowns and Impairment history spans 4 years, with the latest figure at $151.8 million for Q4 2018.

  • For Q4 2018, Asset Writedowns and Impairment changed N/A year-over-year to $151.8 million; the TTM value through Sep 2019 reached $156.1 million, up 984.03%, while the annual FY2018 figure was $151.8 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2018 was $151.8 million at Ironwood Pharmaceuticals, up from $2.5 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $151.8 million in Q4 2018 and bottomed at $1.8 million in Q2 2018.
  • The 4-year median for Asset Writedowns and Impairment is $7.0 million (2014), against an average of $30.0 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 43.82% in 2015 against a maximum downside of 43.82% in 2015.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $8.9 million in 2014, then crashed by 43.82% to $5.0 million in 2015, then surged by 102.0% to $10.1 million in 2016, then skyrocketed by 1402.97% to $151.8 million in 2018.
  • Per Business Quant, the three most recent readings for IRWD's Asset Writedowns and Impairment are $151.8 million (Q4 2018), $2.5 million (Q3 2018), and $1.8 million (Q2 2018).